Michael A. Metzger is a corporate insider at Syndax Pharmaceuticals Inc (SNDX). Metzger has also held reporting roles at Pyxis Oncology, Inc. (PYXS). Metzger has reported 7 insider filings with the SEC since 2025. The most recent filing was in July 2026.
Every role Michael A. Metzger has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Syndax Pharmaceuticals Inc (SNDX)2 filingsUpdated Aug 30, 2026
Michael A. Metzger is Chief Executive Officer of Syndax Pharmaceuticals Inc (SNDX). 7 SEC Form 4 filings on record going back to 2025, most recently on 9 July 2026. Most recent open-market trade: sold $785K of SNDX on 9 July 2026. Lifetime open-market sales: $4.08M.
Every recent SEC Form 4 transaction Michael A. Metzger has reported, most recent first.
InsiderAlpha's records for Michael A. Metzger go back to 2025: 7 primary Form 4 filings, an average of 3.5 per year. 3 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Michael A. Metzger files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Michael A. Metzger is a corporate insider, tracked as Chief Executive Officer of Syndax Pharmaceuticals Inc (SNDX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases and 6 open-market sales ($4.08M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial